Davey Daniel, MD
Hematology & Oncology · Chattanooga, TNNPI 1942258751
Payments from drug & device makers
Across 738 payments — averaging $6769.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1.2M
- AstraZeneca$911K
- Astrazeneca UK Limited$832K
- E.r. Squibb & Sons, L.L.C.$665K
- Merck$293K
- Daiichi Sankyo Inc.$289K
- plus $846K from 29 others
Across 13 payments — averaging $1831.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$16K
- Bristol Myers Squibb$6K
- Eli Lilly$2K
What the payments were for
- Speaking & faculty fees$6,79462%
- Food & beverage$4,01837%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 184 | $1,159,329 |
| AstraZeneca | 67 | $910,838 |
| Astrazeneca UK Limited | 29 | $832,066 |
| E.r. Squibb & Sons, L.L.C. | 38 | $664,638 |
| Merck | 60 | $293,227 |
| Daiichi Sankyo Inc. | 77 | $289,280 |
| F. Hoffmann-la Roche AG | 35 | $220,123 |
| AbbVie | 28 | $173,419 |
| GSK | 105 | $171,022 |
| Novartis | 21 | $122,954 |
| Amgen | 15 | $56,645 |
| Janssen Research & Development, LLC | 4 | $37,951 |
| Array Biopharma Inc | 31 | $34,069 |
| Eli Lilly | 3 | $25,441 |
| Bristol Myers Squibb | 2 | $1,461 |
| Clovis Oncology, Inc. | 1 | $1,274 |
| Foundation Medicine, Inc. | 2 | $350 |
| Pfizer | 8 | $286 |
| Genentech USA, Inc. | 3 | $199 |
| ASD Specialty Healthcare, LLC | 1 | $194 |
| Gilead(2 entities) | 4 | $166 |
| Janssen Scientific Affairs, LLC | 1 | $141 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Siemens Medical Solutions USA, Inc. | 1 | $83 |
| Tersera Therapeutics LLC | 3 | $55 |
| Lilly USA, LLC | 2 | $47 |
| Regeneron | 1 | $43 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Caris MPI, Inc. | 1 | $37 |
| Novocure Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Incyte Corporation | 1 | $25 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$6,794
- FOUNDATIONONE CDX$350
- Enhertu$222
- Neulasta$153
- FOUNDATIONONE$121
- FOUNDATIONONE HEME$121
- FOUNDATIONFOCUS$121
- FOUNDATIONONE LIQUID CDX$121
- Yescarta$111
- KRAZATI$109
How this compares
$4,995,627 in reported general payments places this provider in the 90th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 24 | $362,855 |
| JakafiRuxolitinib Phosphate | 20 | $345,519 |
| OrserduElacestrant Hcl | 15 | $344,126 |
| KisqaliRibociclib Succinate | 22 | $344,101 |
| TasignaNilotinib Hcl | 17 | $339,701 |
| TibsovoIvosidenib | 14 | $281,475 |
| XtandiEnzalutamide | 22 | $269,276 |
| LynparzaOlaparib | 14 | $235,724 |
| TagrissoOsimertinib Mesylate | 13 | $224,173 |
| VerzenioAbemaciclib | 13 | $202,188 |
| AlecensaAlectinib Hcl | 12 | $196,750 |
| Abiraterone Acetate | 99 | $159,828 |
| EliquisApixaban | 70 | $50,052 |
| Imatinib Mesylate | 11 | $13,656 |
| CreonLipase/Protease/Amylase | 12 | $10,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna | $122,954 | $683,80239 claims |
| AstraZenecaLynparza, Tagrisso | $910,838 | $459,89727 claims |
| Incyte CorporationJakafi | $25 | $345,51920 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $47 | $202,29727 claims |
| Genentech USA, Inc.Alecensa | $199 | $196,75012 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $141 | $159,82899 claims |
| PfizerEliquis | $286 | $50,05270 claims |
| AbbVieCreon | $173,419 | $10,46012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Chattanooga
- Bertrand AnzChattanooga$9.6M
- Edward ArrowsmithChattanooga$5.7M
- Brooke DanielChattanooga$4M
- Mark WomackChattanooga$1.9M
- Robert GrahamChattanooga$799K
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.